Ovarian cancer accounts for more deaths than any other gynecologic cancer. In 2025, the World Health Organization estimates the disease ...

A network meta-analysis of 19 weight-loss drugs concludes that most obesity drugs don’t improve quality of life or cardiovascular health.

PARP inhibitors reshaped oncology when they first reached patients some 10 years ago, but they represent just one entry point into a much larger and more intricate biological network.

Disclaimer: The information contained in this article reflects the latest available scientific evidence, personal experiences and opinions of the speakers and not necessarily those of IPSEN.

Union leaders point to Ramaswamy's 2024 relocation of Strive Asset Management from Columbus to Dallas as evidence he won't ...

The BSc (Hons) Computer Science with Foundation Year at Liverpool John Moores University is the ideal course if you are interested in this subject but lack the necessary qualifications to study it at ...

Alector faces a strategic reset after GSK’s termination of their neuroscience collaboration, shifting the investment case to ...

Outsource the writing and you skip the reckoning. The homework exists to build self-awareness. Handing it off defeats the ...

Partnership is integral to GSK. Bringing people together is the best way to innovate and deliver products that transform the standard of care and improve lives. Over half of GSK’s clinical vaccine ...

Research clearly suggests that there are proven ways of developing one's leadership potential and capacity, but it takes hard ...

The Cystic Fibrosis Foundation organised a multidisciplinary committee to develop this Position Paper to outline current ...

The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP ...